Skip to content

Ibogaine research: what the evidence shows

A psychoactive alkaloid researched chiefly for its potential to interrupt opioid and stimulant dependence.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Ibogaine, iboga, noribogaine, then ranked by relevance.

Ibogaine research is dominated by small, uncontrolled observational studies and case series, which consistently report rapid relief of opioid withdrawal and short-term reductions in drug use after a single treatment, alongside preclinical animal work showing reduced self-administration of morphine, cocaine, and alcohol. However, there are no randomized controlled trials, and the same literature documents serious safety concerns, including cerebellar neurotoxicity in rats, QT prolongation and torsades risk, developmental cardiotoxicity in zebrafish, and reported fatalities. The evidence is therefore promising but preliminary: efficacy claims rest on small samples with high attrition and no blinding, and durability beyond 12 months is largely unstudied.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport. 2019 structural study (cryo-electron microscopy) Supports Cryo-electron microscopy structures of SERT-ibogaine complexes in multiple conformations define the structural rearrangements during transport and show ibogaine is a non-competitive transport inhibitor that binds competitively with SSRIs.
Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine 1999 in vitro study Supports Ibogaine produced noncompetitive, insurmountable blockade of human muscle-type and ganglionic nicotinic acetylcholine receptors in the low to intermediate micromolar range.
Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. 1993 experimental animal study Opposes Ibogaine and harmaline caused selective degeneration of a subset of Purkinje cells in parasagittal stripes of the cerebellar vermis, indicating neurotoxic effects.
Treatment of acute opioid withdrawal with ibogaine. 1999 case series 33 Supports Resolution of opioid withdrawal without further drug seeking occurred within 24 hours in 25 of 33 patients and was sustained over 72 hours, with one fatality possibly involving surreptitious heroin use.
Effects and aftereffects of ibogaine on morphine self-administration in rats. 1991 preclinical experimental study Supports Ibogaine dose-dependently reduced morphine self-administration, with a persistent aftereffect lasting days to weeks in some rats that was not attributable to motor impairment or conditioned aversion.
Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. 1994 experimental study Supports All tested iboga alkaloids and harmaline dose-dependently reduced morphine and cocaine self-administration, with some compounds producing persistent decreases lasting several days.
The ibogaine medical subculture. 2008 ethnographic study with systematic quantitative data collection 3414 Supports An estimated 3,414 individuals had taken ibogaine as of February 2006, with 68% doing so for a substance-related disorder and 53% specifically for opioid withdrawal, the most common reason.
Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption 2005 experimental study Supports Ibogaine reduced ethanol intake in two-bottle choice, operant self-administration, and relapse models, and this effect was mediated by upregulated GDNF signaling in the ventral tegmental area.
Inhibitory effects of ibogaine on cocaine self-administration in rats. 1993 experimental study Supports A single 40 mg/kg injection of ibogaine significantly decreased cocaine intake for more than 48 hours, with repeated weekly administration producing a more pronounced reduction.
A preliminary investigation of ibogaine: case reports and recommendations for further study. 1994 case series 7 Supports After single ibogaine doses of 700-1800 mg, none of seven subjects showed significant opiate withdrawal at the end of the psychoactive period, and three of six taking 1000 mg or more appeared drug-free at 14 weeks or longer.
The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity 1997 experimental study with pharmacological ablation Opposes Pharmacological ablation of the inferior olive almost completely prevented ibogaine-induced Purkinje cell degeneration and glial activation, indicating the neurotoxicity is indirect and dependent on the olivocerebellar projection.
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. 2018 observational study 30 Supports Subjective opioid withdrawal scores fell from 31.0 to 14.0 about 76 hours after a mean total dose of 1,540 mg ibogaine HCl, 50% reported no opioid use at 1 month, and drug use, legal, and family/social scores improved through 12 months.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. 2018 observational study 14 Supports A single ibogaine treatment significantly reduced opioid withdrawal scores acutely and produced significant reductions in addiction severity and depression scores at 12-month follow-up among completers, with one death during treatment.
Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. 2007 laboratory study Supports Ibogaine inhibited serotonin transport noncompetitively by decreasing transport rate and stabilized the cytoplasm-facing state of the transporter, in contrast with cocaine.
Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. 2000 observational study Supports A single oral ibogaine dose significantly decreased craving for cocaine and heroin during inpatient detoxification and reduced depressive symptoms that remained lower 30 days after discharge.
Ibogaine for Substance Use Disorders. 2026 review Mixed Argues that ibogaine is a promising candidate for substance use disorders with potential to rapidly reduce withdrawal and cravings after a single dose, but that evidence rests on small observational studies and case reports and carries significant cardiotoxicity, neurological, and fatality risks.
A Harm-Reduction–Oriented Clinical Framework for Ibogaine Administration and Risk Management 2026 theoretical Unclear Argues that most serious adverse events from ibogaine arise from preventable factors in patient selection, preparation, dosing, monitoring, and post-treatment care, and proposes a harm-reduction clinical framework emphasizing dynamic risk assessment, cardiac electrophysiology, and metabolic variability.
Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism 2026 preclinical experimental study Supports Ibogaine produced rapid concentration-dependent metabolic suppression followed by a delayed energy rebound in neurons, and oral ibogaine in mice caused transient spinal cord protein changes consistent with metabolic stress that resolved by 72 hours, which the authors propose may reflect metabolic preconditioning that enhances plasticity and repair.
Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 cross-sectional survey Unclear Describes self-reported health outcomes attributed to recent use of ibogaine and other psychedelics in a nationally representative survey, with no specific outcomes or effect sizes reported in the available text.
QT Prolongation With Methadone, Donepezil, and Ibogaine 2026 commentary Opposes States that ibogaine carries a high risk of QT prolongation and torsades de pointes, and that a magnesium pre-dosing protocol was developed to reduce this risk.
Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan. 2026 narrative review Unclear Argues that FDA approval of a psychedelic or psychedelic-adjacent agent would not automatically change Japanese regulation but would create pressure, and contends ibogaine would pose the greatest pharmacy challenge, requiring CYP2D6 phenotype assessment, QT drug-interaction screening, and cardiac monitoring.
Ibogaine as a Double-Edged Sword: Developmental Cardiotoxicity and Neurobehavioral Alterations in Zebrafish 2026 observational study using a zebrafish model Opposes Ibogaine induced early-onset bradycardia at 100 ng/mL and pericardial edema at 500 ng/mL, and disrupted neurobehavioral endpoints at concentrations lower than those causing morphological toxicity.
Dynamic Substates of the Default Mode Network Are Associated with Mystical Experiences and Clinical Outcomes after Magnesium-Ibogaine Treatment in Veterans with Traumatic Brain Injury 2026 observational trial 30 Supports Magnesium-ibogaine did not alter static default mode network connectivity but produced sustained decreases in the switching rate of a dynamic DMN substate, correlated with mystical experience scores and clinical improvements at one month.
Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report 2026 case report 1 Supports After an 800 mg ibogaine HCl flood dose plus two 300 mg boosters, the patient reported immediate cessation of cravings and serial toxicology and psychometrics were consistent with abstinence from ketamine, cocaine, and alcohol over about 17 months, with improved depression and quality of life.
Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology 2026 review Unclear Argues that two development strategies exist for ibogaine-based therapies, broad polypharmacological compounds and selective bespoke analogs, each with distinct translational trade-offs, and that the field should resist oversimplified narratives about derivative superiority.

Points of agreement

  • Preclinical studies consistently show ibogaine and related iboga alkaloids reduce self-administration of morphine, cocaine, and alcohol in rodents, often with effects outlasting the drug's presence.
  • Uncontrolled clinical reports and observational studies consistently describe rapid relief of opioid withdrawal after a single ibogaine dose.
  • Several observational studies report reduced drug use, craving, and depressive symptoms persisting weeks to 12 months after treatment.
  • Multiple sources agree ibogaine carries serious cardiac risk, particularly QT prolongation and torsades de pointes.
  • Sources agree ibogaine acts on multiple targets, including serotonin, opioid, glutamatergic, nicotinic, and sigma systems, and is metabolized to longer-lasting noribogaine.
  • Reviewers and commentators agree the clinical evidence base is limited to small observational studies and case reports and that controlled trials are needed.

Conflicts

  • Animal work reports anti-addictive benefit while separate animal work documents cerebellar Purkinje cell degeneration from ibogaine, so benefit and neurotoxicity are reported in the same preclinical literature.
  • Clinical reports emphasize withdrawal relief and abstinence, while case series and observational studies also record fatalities, and one review stresses significant toxicity.
  • Some rodent studies attribute acute reductions in drug intake to motor impairment or tremor, whereas others report aftereffects that cannot be explained by motor effects or conditioned aversion.

Gaps

  • No randomized controlled trials of ibogaine for any indication.
  • Small samples, open-label designs, no blinding, and substantial attrition in follow-up cohorts.
  • Durability beyond 12 months is largely unexamined, and long-term abstinence claims rest on single case reports.
  • Dose-finding and standardization are absent, with widely varying doses and protocols across reports.
  • Cardiac safety data are limited; QT risk is described but not systematically quantified in treated cohorts.
  • Human neurotoxicity data are lacking; cerebellar toxicity is documented only in rodents.
Browse these studies in the library

Common questions

What does the research agree on about ibogaine?
  • Preclinical studies consistently show ibogaine and related iboga alkaloids reduce self-administration of morphine, cocaine, and alcohol in rodents, often with effects outlasting the drug's presence.
  • Uncontrolled clinical reports and observational studies consistently describe rapid relief of opioid withdrawal after a single ibogaine dose.
  • Several observational studies report reduced drug use, craving, and depressive symptoms persisting weeks to 12 months after treatment.
  • Multiple sources agree ibogaine carries serious cardiac risk, particularly QT prolongation and torsades de pointes.
  • Sources agree ibogaine acts on multiple targets, including serotonin, opioid, glutamatergic, nicotinic, and sigma systems, and is metabolized to longer-lasting noribogaine.
  • Reviewers and commentators agree the clinical evidence base is limited to small observational studies and case reports and that controlled trials are needed.
Where do studies on ibogaine conflict?
  • Animal work reports anti-addictive benefit while separate animal work documents cerebellar Purkinje cell degeneration from ibogaine, so benefit and neurotoxicity are reported in the same preclinical literature.
  • Clinical reports emphasize withdrawal relief and abstinence, while case series and observational studies also record fatalities, and one review stresses significant toxicity.
  • Some rodent studies attribute acute reductions in drug intake to motor impairment or tremor, whereas others report aftereffects that cannot be explained by motor effects or conditioned aversion.
What is still unknown about ibogaine?
  • No randomized controlled trials of ibogaine for any indication.
  • Small samples, open-label designs, no blinding, and substantial attrition in follow-up cohorts.
  • Durability beyond 12 months is largely unexamined, and long-term abstinence claims rest on single case reports.
  • Dose-finding and standardization are absent, with widely varying doses and protocols across reports.
  • Cardiac safety data are limited; QT risk is described but not systematically quantified in treated cohorts.
  • Human neurotoxicity data are lacking; cerebellar toxicity is documented only in rodents.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Ibogaine, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Ibogaine or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: June 2026 →

610 articles · 117 from the last two years · 156,123 participants across 116 studies reporting sample size

Common study designs

review 109 preclinical study 17 systematic review 23 experimental study 113 theoretical or philosophical paper 25

Research volume by year

Compare topics →

304 studies whose primary subject is ibogaine since 2002

Studies about ibogaine per year, 2002 to 2026, peaking at 36 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 20 40 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about ibogaine per year, 2002 to 2026, peaking at 36 in 2026
Year Studies
2002 6
2003 7
2004 5
2005 3
2006 8
2007 3
2008 7
2009 4
2010 5
2011 7
2012 6
2013 5
2014 5
2015 13
2016 21
2017 11
2018 22
2019 11
2020 12
2021 17
2022 14
2023 22
2024 24
2025 30
2026 36

Research

Synthesize the evidence → Search all →

Ibogaine for Substance Use Disorders.

Advances in Therapy October 14, 2026 Ahmed I Anwar, Abdul-Rahman A Hegazi, M Farris Sawaya et al.

Substance use disorders (SUDs) are a major global health burden, and psychedelic-assisted therapies are now gaining scientific interest, with ibogaine being considered as a candidate for anti-addictive effects across multiple substance classes. Ibogaine is a multi-target indole alkaloid acting on opioid, glutamatergic, serotonergic, and sigma systems with potential to rapidly reduce withdrawal...

DOI: 10.1007/s12325-026-03814-x (opens in new tab) Full text (opens in new tab) Addiction Mental illness Methamphetamine Opioid +2

A Harm-Reduction–Oriented Clinical Framework for Ibogaine Administration and Risk Management

October 3, 2026 Mark Picard preprint

Ibogaine is a psychoactive indole alkaloid with reported potential to interrupt opioid withdrawal and reduce substance use. Despite increasing interest in its therapeutic applications, ibogaine administration remains associated with significant risk, particularly related to cardiac conduction abnormalities and autonomic instability. Most serious adverse events appear to arise from identifiable...

DOI: 10.31219/osf.io/b67ts_v1 (opens in new tab)

Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism

bioRxiv (Cold Spring Harbor Laboratory) October 2, 2026 Madison J Oulton, Gracious D. S. Kasheke, Kelly A. Meaney et al. preprint

We have examined how ibogaine may enhance synaptic plasticity and neural repair. Extracellular efflux analysis showed that ibogaine (3, 10 or 30 μM) produced a rapid (<5 minutes) and concentration-dependent suppression of mitochondrial function and glycolysis in mouse cortical neurons. Cell-based imaging demonstrated this metabolic inhibition was preceded by an elevation of the mitochondrial...

DOI: 10.64898/2026.09.29.755437 (opens in new tab) Full text (opens in new tab)

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

JAMA Network Open September 29, 2026 Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.

This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.

DOI: 10.1001/jamanetworkopen.2026.36756 (opens in new tab)

QT Prolongation With Methadone, Donepezil, and Ibogaine

September 2, 2026 Scott R. Beach

When QT risk is a concern, consider buprenorphine over methadone. QT prolongation occurs in approximately 34% of methadone maintenance patients, and torsades in roughly 2%. Ibogaine carries a high risk of QT prolongation and torsades. Stanford developed a protocol to pre-dose patients with magnesium to reduce this risk. Evidence on donepezil's QT risk remains mixed. Case reports link it to QT...

DOI: 10.64239/pi-vl11508 (opens in new tab)

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.

Cureus September 2026 Robert B. Raffa

An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These...

DOI: 10.7759/cureus.116178 (opens in new tab) Full text (opens in new tab) Ibogaine Drug interactions Drug regulation Japan pharmacy practice +2

Ibogaine as a Double-Edged Sword: Developmental Cardiotoxicity and Neurobehavioral Alterations in Zebrafish

Behavioural Brain Research August 1, 2026 Alessandra Mara de Oliveira, Flavia R. Abe, Rafael G. Dos Santos et al.

Ibogaine has attracted increasing attention as a potential treatment for substance use disorders; however, its clinical application remains limited by well-documented cardiotoxicity, and its safety during early development is poorly understood. Here, we investigated the developmental cardiotoxic and neurobehavioral effects of ibogaine using zebrafish embryos and larvae as a translational model....

DOI: 10.1016/j.bbr.2026.116429 (opens in new tab)

Dynamic Substates of the Default Mode Network Are Associated with Mystical Experiences and Clinical Outcomes after Magnesium-Ibogaine Treatment in Veterans with Traumatic Brain Injury

medRxiv July 22, 2026 Kenneth Shinozuka, Clayton Olash, Tracy Han et al. preprint

Preliminary evidence suggests that the combination of magnesium and ibogaine, an atypical psychedelic, may be a promising treatment for post-traumatic stress disorder (PTSD), opioid use disorder, and traumatic brain injury (TBI). The "mystical" experience elicited by ibogaine, which is characterized by feelings of awe, selflessness, and transcendence, is correlated with improvements in PTSD...

DOI: 10.64898/2026.07.20.26358512 (opens in new tab)

Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report

Frontiers in Psychiatry July 20, 2026 Sergio Pérez Rosal, Sonya C. Faber, Markus Backmund

Substance use disorders (SUD) involving ketamine, cocaine, and alcohol present significant clinical challenges, often characterized by high relapse rates and limited pharmacological options. This case report details a 30-year-old male with a five-year history of severe polysubstance dependence, including daily intranasal ketamine use (2–3 g/day), cocaine, and alcohol, comorbid with recurrent...

DOI: 10.3389/fpsyt.2026.1846320 (opens in new tab)

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology

Expert Opinion on Drug Discovery July 4, 2026 Christopher D. Verrico, Lynnette A. Averill, Cameron J Moore et al.

INTRODUCTION: Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and uncertainty regarding its complex pharmacology. Recent interest has surged in developing ibogaine analogs...

DOI: 10.1080/17460441.2026.2693144 (opens in new tab) Addiction Clarity Drug development Psychopharmacology +4

Clinical trials

All Ibogaine trials →